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CHF. Despite being significantly younger, they presented with high risk features and had 
a higher in hospital complication rate although similar unadjusted mortality rate. This 
study suggests that pts of SA ethnicity are a high risk subset of the CHF population who 
may benefit from more aggressive therapeutic intervention at an eedier age. 
1205-155 Mltral  Regurg i tat ion Is an Independent Risk Factor fo r  
Mortality in Patients With Heart Failure and Left  
Ventr icu lar  Systo l i c  Dysfunction 
Beniamin H. Tdchon, G. Michael Felker, Linda K. Shaw, Christopher H. Cabell, 
Christopher M. O'Connor, Duke Clinical Research Institute, Durham, North Carolina. 
Background: Mitral regurgitation (MR) is common in patients with heart failure (HF). 
However, mild MR accompanying left-ventdcular (LV) dysfunction is often minimized in 
practice and the relation between the severity of MR and survival is not well character- 
ized. 
Methods: We assessed the incidence of MR in patients with HF (-> NYHA II) and ejection 
fraction @,0% undergoing cardiac catheterization between 1986 and 2000. MR was 
graded as mild (grade 1+/2+) or moderate/severe (grade 3+/4+). 
Patients with other valvular disease were excluded. Baseline charactedstics of the popu- 
lation were defined. A multivariate Cox proportional hazards model was used to assess 
the independent effect of MR on survival. 
Results: 2057 patients met study cdteria. 1156 (56%) had MR identified. In 811 (70%), 
the MR was mild. Patients with MR were more likely to be older (63 vs. 60, p=O.001), 
female (43.4% vs. 28.9%, p=0.001), and have a gallop on exam (36.5% vs. 24.8%, 
p--O.001). Mean duration of follow-up = 3.4 years. 
Compared to those without MR, patients with mild and moderate/severe MR had an 18% 
(HR=1.18, 1.03-1.36, p=0.01) and 53% (HR=1.53, 1.29-1.82, p<0.001) increased risk of 
death, respectively (GRAPH). 
Conclusions: 
MR is common in patients with HF and systolic dysfunction. There is an independent, 
progressive relation between MR severity and mortality. Studies are needed to investi- 
gate the affect of therapies (mltral valve repair or cardiac re-synchronization) on out- 
comes in patients with MR accompanying LV dysfunction. 
MR Grade  and  eur~rlVal  In HF  Pa l te r  
1205-156 Prognosis of Women Compared With Men With Heart 
Failure end Acute Myocardial Infarction After Previous 
Revascularlzatlon 
Predrao M. Mitrovic, Zorana Vaslljevic-Pokrajcic, Branislav Stefanovic, Jovan Perunicic, 
Gordana Matic, Nebojse Radovanovic, Dubravka Rajic, Cardiology Clinic, institute for 
Cardiovascular Diseases, University Clinical Centre, Belgrade, Yugoslavia. 
Patients (pts) who have clinical evidence of congestive heart failure (CHF) after acute 
myocardial infarction (AMI) and previous coronary artery bypass grafting (CABG) have a 
poor prognosis. The aim of this prospective study was to analyze influence of gender on 
survival in pts with CHF and AMI after previous CABG. Methods: From April 1990 - 
August 2001 we studied 730 pts, who developed AMI after CABG, mean age 58.4+8.0 
years, mainly men (80.8%). The pts with eerly perioperative AMI were excluded from the 
study. All pts were followed-up 12 years. The average time interval from CABS to AMI 
was 96.2 ± 16.0 months. The average number of grafts was 3,4 grafts/pts. There were 
274/730 pts (37.5%) with signs of CHF. Clinical evidence of CHF was defined as at least 
two of the following: bibasilar ralas, third heart sound or/and interstitial or alveolar edema 
on chest radiograph. All pts were divided in two groups: group I - 89/274 (32.5%) female 
with CHF and AMI after previous CABG and group II - 185/274 (67,5%) male with CHF 
and AMI after previous CABG. Results: There was no statistical difference in age, 
CABG-AMI interval, number of grafts/pie, AMI location, infarct size and risk factors for 
coronary artery disease. There were differences between groups in: previous angina 
pectods (91% vs 56.8%, p<0.01), previous AMI (56.2% vs 31.3%, p<0.05), in-hospital 
mortality (15.7% vs 4.3%, p<0,05) and one-year mortality (40.4% vs 11.9%, p<0.01). 
Conclusion: This study suggests that female with signs of CHF and AMI after previous 
CABG had worse prognosis compared with male with CHF and AMI after previous 
CABG, specially in in-hospital and one-year padod; the predictors of that prognosis were 
previous angina pectods and previous AMI. 
1205-157 The Incremental Prognostic Sign i f i cance of  
Hyperurlcemla In African Americana With Severe Heart 
Fai lure 
Patricia A. Uber. Mandeep R. Mehra, Myung H. Park, Robert L. Scott, Ochsner 
Cardiomyopathy and Heart Transplantation Center, New Orleans, Louisiana. 
Background: Compared with Caucasians (C), African Americans (AA)exhibit higher uric 
acid levels, a marker of free radical generation. We sought to determine the clinical 
impact of hyperuricamia in AA with severe Heart Failure (HF).Methoda: 140 severe HF 
patients (52 +11 years, ejection fraction 20 :L-9%, 80% men, follow-up 12-72 months) 
awaiting heart transplantation were examined in order to evaluate the prognostic utility of 
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baseline uric acid levels (_>7.5 versus < 7.5 mg/dl) at listing for transplantation, as a func- 
tion of race. We analyzed detailed variables among the 106 C and 34 AA patients to 
assess variables predictive of HF hospitalizations or death in concert with hyperurice- 
mia.Reaulta: Baseline charactedstics were similar in AA and C with regard to age, EF%, 
NYHA class, serum sodium, bilirubin, creatinine and HF medications. AA were more 
likely than C's to, have hypertension (61% vs 40%, p =0.04), had a larger proportion of 
women (39% vs 13%, p = 0.007), and were more hyperudcemic (7.9 + 2.1 vs 6.8 ± 2.0, p 
= 0.006). The results of actuarial event free survival at 3 years are shown in the table. 
Group African Americana Caucasians p value 
Urlc Acld > 7.5mg/ 60% 71% 0.04 
dl 
Uric Acid < 7.5 rag/ 86% 80% ns 
dl 
p value 0.03 ns 
Multivariable analysis demonstrated that hyparudcamia occurred independent of diuretic 
use, renal function, age and gender.Conclusions: Hyperuricamia, a marker of oxidative 
stress, is prevalent in AA and represents a discriminatory marker of poor clinical outcome 
in severe HF. This investigation provides insight into ethnic differences in oxidative stress 
as a critical determinant of prognosis in heart failure. 
1205-158 Predict ion of  Morbidity and Morta l i ty  Fo l lowing 
Myocardial Infarction 
Kenneth Dickstain, Stevan Snappin, The OPTIMAAL Trial Study Group, Central Hospital 
in Rogaiand, Stavanger, Norway. 
Introduction: It is important to choose the most appropriata endpoints in clinical trials 
evaluating an intervention on morbidity and mortality. The ability of these events to pre- 
dict death impacts on patient selection and trial design. 
Methods: 5477 patients with acute myocardial infarction and left ventricular dysfunction 
have been randomised to treatment with either captopdl or Iosertan in the OPTIMAAL 
trial. During a mean follow-up period of 27 months there have been 584 patients with 
reinfarctions, 1561 patients with ravascularisation (PTCA/CABG), 2670 patients with car- 
diovascular (CV) hospltalisations and 780 deaths. 
Results; Baseline demographics contain powerful predictors for reinfarction, revascular- 
isation or hcspitalisetion. The ability of selected variables to predict a heart failure (HF) 
hospitalisation are displayed in the table. The increases in risk of death associated with 
cardiovascular endpoints were: HF hospitalisetion 746%, Rainfarction 502%, CV Hospi- 
talisation 290%, Revasculadsation -45% (P<0.001 in all cases). 
Conclusion: Morbid events following complicated MI are predicted by selected baseline 
demographic variables. Death is predicted by these morbid endpoints. A heart failure 
hospitalisetion was an especially powerful predictor for death. These data have implica- 
tions for the choice of patients and endpoints in clinical tdals seeking to assess the effi- 
cacy of an intervention on morbidity and mortality. 
Increases In Risk of a Heart Failure Hoapltalleatlon 
Baseline Risk Factor Clinical Status Prior to Randomization 
age (per year) 6% tachycardia 83% 
diabetes 62% X-ray congestion 81% 
atrial fibrillation 62% IV diuretics 77% 
prior diuretic 62% pulmonary rales 60% 
previous infarction 47% EF<35% 52% 
previous infarction 41% gallop rhythm 48% 
prior beta blocker 39% Killip class (per class) 58% 
P<O.O01 in all cases 
1205-159 Low Serum Total Cholesterol Is Associated With a 
Marked Increase in Mortality in Advanced Heart Fai lure 
Tamare B. Herwich, Machete A. Hamilton, Robb MacLellan, Gregg C, Fonarow, UCLA 
Medical Center, Los Angeles, California. 
Background: Although hypercholesterolemia is associated with CAD and cardiovascu- 
lar mortality, the relationship between choleeterot and heart failure (HF) mortality is less 
certain. 
Methods: Our study analyzed 1134 patients with advanced HF referred to a single cen- 
ter for transplant evaluation. The cohort was 75% men, etiology was 48% ischemic, and 
mean EF was 22%. Serum lipid panel was measured time of initial presentation. Patients 
were stratified into five groups based on quintiles of total cholesterol (TC) level. 
Resulta: HF etiology, HTN, DM, and lipid-lowering therapy at time of referral were similar 
among the 5 TC groups. Patients with lower TC had significantly lower levels of LDL, 
HDL, triglycarides (TG), sodium and albumin. The lower TC quintiles had lower EF and 
cardiac output, but higher wedge pressures and increased likelihood of NYHA class IV. 
Decreased TC, LDL, HDL, and TG each predicted increased mortality (p=0.01) on 
univadate analysis. After adjustment for known predictors of HF mortality including BMI, 
elevated TC was an independent predictor of improved survival (0.996 RR tor lmg/di 
increase), while LDL, HDL, and TG were not. See table for survival and relative dsk of 
each TC quintile. 
Conclusions: Low serum TC predicts HF outcomes independent of established mortality 
predictors, and thus represents a novel prognostic factor. Further investigations are nec- 
essary to determine whether a low TC level is merely a prognostic marker or is playing a 
causative role in HF mortality. 
